GW Pharmaceuticals ended 2017 by filing its ... GW specialises in drugs developed from cannabis plants, and already has Sativex (nabiximols) approved in markets including the UK for multiple ...

Source: Michael Vi / Shutterstock.com Jazz Pharmaceuticals (NASDAQ:JAZZ) entered the cannabis sector in 2021 when it acquired GW Pharmaceuticals, and it has since established its presence in ...

But there have been no FDA-approved medications derived from marijuana—until now ... CEO of manufacturer GW Pharmaceuticals. Next, the company is exploring how effective CBD and other ...

GW Pharmaceuticals' Epidyolex has been approved in the EU for a third epilepsy indication, giving a boost for the company ahead of its $7.2 billion takeover by Jazz Pharma. The cannabis-derived ...

following the acquisition of GW Pharmaceuticals plc. in 2021. Why it matters: This strategic partnership is set to be the first-ever MoU for medical marijuana research between any Australian and ...

invests in companies from across the entire marijuana industry, including: GW Pharmaceuticals (cannabinoid-focused medicine). Cronos Group (production and distribution). Canopy Growth Corporation ...

Because extracts are the primary source of cannabis compounds, most companies have focused on improving those sources rather than seeking new ones. For example, GW Pharmaceuticals, the company ...

GW Pharmaceuticals is a cutting-edge UK-based ... and the development of regulatory approved medicines derived from cannabis. GW has established a world leading position in the development of ...